Reactive astrocytosis develops in many neurologic diseases, including epilepsy. Astrocytotic contributions to pathophysiology are poorly understood. Studies examining this are confounded by comorbidities accompanying reactive astrocytosis. We found that high-titer transduction of astrocytes with enhanced green fluorescent protein (eGFP) via adeno-associated virus induced reactive astrocytosis without altering the intrinsic properties or anatomy of neighboring neurons. We examined the consequences of selective astrocytosis induction on synaptic transmission in mouse CA1 pyramidal neurons. Neurons near eGFP-labeled reactive astrocytes had reduced inhibitory, but not excitatory, synaptic currents. This inhibitory postsynaptic current (IPSC) erosion resulted from a failure of the astrocytic glutamate-glutamine cycle. Reactive astrocytes downregulated expression of glutamine synthetase. Blockade of this enzyme normally induces rapid synaptic GABA depletion. In astrocytotic regions, residual inhibition lost sensitivity to glutamine synthetase blockade, whereas exogenous glutamine administration enhanced IPSCs. Astrocytosismediated deficits in inhibition triggered glutamine-reversible hyperexcitability in hippocampal circuits. Thus, reactive astrocytosis could generate local synaptic perturbations, leading to broader functional deficits associated with neurologic disease.
a r t I C l e S Astrocytes regulate synaptic function throughout the brain [1] [2] [3] and are involved in neurotransmitter recycling. Following synaptic release, glia restrict the diffusion of, sequester, inactivate and recycle a variety of small molecule neurotransmitters, including glutamate, GABA and catecholamines [4] [5] [6] . In the case of glutamate and GABA, the astrocytic enzyme regulating recycling is glutamine synthetase, which produces glutamine from glutamate following glial uptake of this neurotransmitter. Glutamine is transported back to presynaptic terminals via glia-and neuron-specific glutamine transporters and converted to glutamate by the mitochondrial enzyme glutaminase 4, 7 to be reused in synaptic function either directly or following conversion to GABA.
This multicellular enzymatic process, termed the glutamateglutamine cycle, is critical for maintaining ongoing synaptic function. Inhibitory synapses fail following disruption of the glutamine cycle 8, 9 , whereas excitatory synapses have sufficient reserve glutamate to transiently retain function 10 . In various CNS disease states, including epilepsy, Parkinson's disease, Alzheimer's disease, stroke and traumatic brain injury, there is growing evidence that glutamateglutamine cycle function is compromised [11] [12] [13] [14] [15] [16] . All of these pathologic conditions are also associated with the development of astrocytic alterations, termed reactive astrocytosis.
Reactive astrocytosis is defined and characterized by gross hypertrophy of the cell body and processes of astrocytes in injured and/or diseased areas of the brain 17 . Accompanying these anatomic changes is enhanced expression of glial cytoskeletal proteins, glial fibrillary acidic protein (GFAP) and vimentin 17, 18 . Enhanced expression of these two proteins can therefore be used to assess the development of reactive gliosis. The disease in which reactive astrocytosis has arguably received the most experimental attention is temporal lobe epilepsy (TLE) 19 . The pathological hallmark of TLE is mesial temporal sclerosis, defined as segmental neuronal loss and reactive astrocytosis in the hippocampus and associated temporal lobe structures.
In TLE, a series of phenotypic changes accompany cell hypertrophy in reactive astrocytes, including the reduced expression of glutamine synthetase and the astrocytic glutamate uptake transporters EAAT1 and EAAT2 (refs. 11-13 , but see ref. 20) , proteins that are critical for the glutamine cycle. Recognition of the importance of these proteins in neurotransmitter uptake and recycling has led to the hypothesis that glutamine cycle deficits associated with the development of reactive astrocytosis may be contributing to the epilepsy disease phenotype 8, 12, 19 . However, studies attempting to test this hypothesis have been hampered by the broad constellation of structural and functional changes that are evident in the hippocampi of individuals with TLE and in animal models of epilepsy.
We found that high-titer viral transduction of astrocytes led to selective virus-induced reactive astrocytosis in the absence of alterations in adjacent neurons and microglia. Using this model, we assessed the effects of virus-induced reactive astrocytosis on synaptic transmission in hippocampal area CA1. We found that astrocytosis induced specific deficits in inhibitory synaptic transmission, precipitating disruptions in functional regulation of circuits in a manner consistent with enhanced excitability. This could contribute to elevated seizure susceptibility in TLE.
a r t I C l e S

RESULTS
Viral induction of reactive astrocytosis
We evaluated transduction patterns of six adeno-associated virus (AAV) pseudotypes: AAV2/1, 2/2, 2/5, 2/7, 2/8 and 2/9. Of these six, AAV2/1, AAV2/5, AAV2/7 and AAV2/9 were the most effective at inducing CMV promoter-driven eGFP expression in the hippocampus ( Supplementary Fig. 1 ). AAV2/9 showed preferential neuronal tropism, whereas AAV2/5 predominantly labeled astrocytes, displaying robust colocalization of eGFP with the astrocytic marker GFAP (85%; Supplementary Figs. 1 and 2) . Substitution of the CMV promoter with a Gfap promoter (Gfa104) increased astrocyte-specific expression to >99% ( Fig. 1) . We observed no colocalization of AAV2/5 eGFP with NG2-positive oligodendrocyte progenitors, mature oligodendrocytes or microglia ( Supplementary Fig. 3 ), again indicating a preferential tropism of AAV2/5 for astrocytes. AAV2/5-transduced astrocytes were characterized by a viral titer-dependent cellular hypertrophy, consistent with their activation by the virus (Figs. 1e-g and 2). Bromodeoxyuridine (BrdU) administered for 1 week during development of astrogliosis labeled only 1% of eGFP/GFAPpositive astrocytes, indicating that virally induced hypertrophy The expression levels of both these proteins significantly increased (P < 0.001) in the hippocampus following injection of the high (3 × 10 10 genome copies per injection), but not the low (10 10 genome copies per injection), titer of AAV2/5-Gfa104-eGFP ( Fig. 2a-h,q,r) .
Reactive astrocytosis was induced locally, in the absence of microglial reactivity ( Supplementary Fig. 4 ). Furthermore, high-titer AAV2/9 did not induce reactive astrocytosis, indicating that astrocyte activation was not an inflammatory response to intrahippocampal injection of virus or to neuronal transduction ( Supplementary Fig. 5 ).
Several studies have suggested that reduced glutamine synthetase levels are associated with the development of astrocytosis in the pathophysiology of epilepsy 11, 12, 21 . Consistent with these findings, we observed a pronounced downregulation of glutamine synthetase expression following injection of high-titer AAV2/5 ( Fig. 2i -p,s) but not of the equivalent AAV2/9 titer ( Supplementary Fig. 5 ). This was also associated with enhanced GFAP and vimentin expression ( Fig. 2 and Supplementary Fig. 6 ). As astrocytic glutamine synthetase is the primary enzyme generating glutamine in the brain, these results indicate that development of reactive astrocytosis will disrupt neuronal glutamine supply and should generate a deficit in inhibitory neurotransmission in neurons located in areas populated by reactive astrocytes (eGFP-positive areas).
Basal and dynamic failure of IPSCs in astrocytotic regions
To evaluate the consequences of reactive gliosis on synaptic efficacy, we began by recording monosynaptic inhibitory responses (evoked IPSCs, eIPSCs) in CA1 pyramidal neurons elicited by local interneuron stimulation. eIPSCs in neurons located in eGFP-positive areas were markedly smaller than eIPSCs recorded in both neurons from control mice and neurons located in eGFP-negative areas of AAV2/5treated mice (Fig. 3a) . The amplitude distribution of eIPSCs in cells from eGFP-positive areas was skewed toward small-amplitude events (skewness = 1.15 ± 0.51, P = 0.002, Kolmogorov-Smirnov test) and was significantly different from that of the control cell population (P = 0.013, Kolmogorov-Smirnov test), with the low amplitude (<50 pA) component accounting for 55% of all responses (Fig. 3b) . Distributions of eIPSC amplitudes of neurons from naive mice, mice injected with AAV2/9 and eGFP-negative areas of AAV2/5-injected mice were not significantly different (average eIPSC in naive, 91.74 ± 12.62 pA, n = 11; AAV2/9, 99.9 ± 12 pA, n = 8, P = 0.66 relative to naive; eGFP-negative areas, 87 ± 15, n = 7, P = 0.81 relative to naive, P = 0.51 relative to AAV2/9) and were pooled for analysis ( Fig. 3b) . The eIPSC amplitude distribution in this composite control group of cells was normal (skewness = 0.46 ± 0.46, P = 0.2, Kolmogorov-Smirnov test), with the majority of eIPSCs in the 51-100-pA range. In addition, paired pulse ratios were similar between cells from high-titer AAV2/5 eGFP-positive areas and control cells, consistent with there being a similar initial probability of release at GABAergic synapses onto both groups of cells (control paired pulse ratio = 0.51 ± 0.02, n = 4; AAV2/5 paired pulse ratio = 0.55 ± 0.06, n = 5; P = 0.56). In a series of control experiments, we injected mice with a low titer of AAV2/5 (10 9 genome copies per injection), which does not induce reactive astrocytosis (Fig. 2) . The frequencies of low (<50 pA) and high (>50 pA) amplitude events in pyramidal cells from eGFP-positive areas did not differ from the respective frequencies in cells from control mice (P = 0.37, n = 12, binomial test, no overall difference in amplitude distributions; P = 0.3, Kolmogorov-Smirnov test, Supplementary Fig. 7) .
We next investigated quantal postsynaptic responses by recording spontaneous miniature IPSCs (mIPSCs) in the presence of tetrodotoxin and glutamatergic antagonists. The amplitude distribution of mIPSCs recorded from neurons in eGFP-positive regions was leftshifted relative to controls ( Fig. 3c,d) . mIPSC frequency was also reduced by 35% in neurons from eGFP-positive regions (AAV2/5, 10.3 ± 1.8 Hz; control, 15.8 ± 1.4 Hz; P = 0.04), probably as a result of a subset of small events in AAV2/5 cells falling below the noise threshold. There was no difference in mIPSC decay time kinetics between the two groups (AAV2/5, τ w = 6.3 ± 1.1 ms; control, τ w = 6.4 ± 1.1 ms). a r t I C l e S These data support the observation that neurons in regions of astrocytic reactivity have a substantial basal deficit in inhibitory neurotransmission. Moreover, preferential impairment of small, but not large, amplitude mIPSCs is consistent with a presynaptic origin of this deficit 22 (see Discussion).
To evaluate inhibitory synaptic function in pyramidal neurons under conditions of sustained activation similar to that seen in vivo, we recorded eIPSCs generated by a long-duration stimulus train. The train consisted of 50-Hz bursts of 4 pulses, every 20 s for 15 min. In control cells, eIPSC amplitudes were significantly increased during the train (204 ± 16% of pre-train values, n = 10, P = 0.004, paired t test) but returned to pre-train values following train stimulation (102 ± 8%; Fig. 3e ). In contrast, eIPSC amplitudes in neurons in eGFP-positive areas (Fig. 3f) were not enhanced during the train (96.5 ± 8.7% of pre-train values, n = 10) and, following the train stimulation, decreased to 57.5 ± 9.4% of pre-train values (P = 0.003 compared with controls; Fig. 3e ).
Astrocytes release a number of molecules that modify neuronal activity, including ATP 2 and glutamate 23 . To assess whether modifications in astrocytic release accompanying viral-induced reactivity could account for the failure of inhibition, we blocked neuronal receptors for these gliotransmitters. In slices from AAV2/5 mice, the addition of purine, adenosine and mGluR II/III antagonists (50 µM pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid), 800 nM 8-cyclopentyl-1,3-dipropylxanthine and 300 µM (RS)-a-cyclopropyl-4-phosphonophenylglycine, respectively) did not significantly alter the amplitude or charge transfer of eIPSCs or evoked excitatory postsynaptic currents (eEPSCs) relative to responses evoked in the absence of these drugs (in the presence of antagonists: eIPSC amplitude = 48.2 ± 9.4 pA, n = 6, P = 0.121; eIPSC charge = 2.45 ± 0.61, n = 6, P = 0.174; eEPSC amplitude = −154.8 ± 70 pA, n = 4, P = 0.168; eEPSC charge = 0.54 ± 0.27, n = 4, P = 0.5).
Excitatory signaling is unaltered by astrocytosis
We next examined eEPSCs in areas exhibiting reactive astrocytosis. Compound synaptic responses were recorded in the absence of glutamate and GABA A receptor antagonists. Under these conditions, eIPSCs followed eEPSCs arising from activation of Schaffer collateral synapses on pyramidal cell dendrites ( Fig. 4a) . eEPSC amplitude and charge in cells in eGFP-positive areas were not significantly different from those of control cells (amplitude, P = 0.34; charge, P = 0.59; Fig. 4b ). In the same compound EPSC/IPSC recordings, IPSC amplitude and charge were significantly depressed in neurons adjacent to AAV2/5 eGFP-positive cells compared with those of controls (amplitude, P = 0.014; charge, P = 0.0006; Fig. 4c ), similar to the 55% of eGFP-positive neurons with small eIPSCs evident in monosynaptic recordings (Fig. 3b) .
We then investigated eEPSCs using stimulation protocols designed to interrogate the dynamics of vesicle pool release and recovery. Two synaptic vesicle populations respond to electrical stimulation: a readily releasable pool (RRP) composed of docked, active zone vesicles available for immediate release and a reserve pool, representing the vesicles that are drawn on when the RRP is depleted 24 . RRP release can be triggered by brief electrical stimulation, whereas reserve pool release requires prolonged stimulation protocols 25 . Using previously published stimulation parameters and in the presence of picrotoxin (100 µM) and d(−)-2amino-5-phosphonovaleric acid(50 µM), we found that recovery from stimulation-induced depletion of the RRP and the reserve pool of vesicles at excitatory synapses occurred with a similar time course in both AAV2/5 and control neurons ( Fig. 4d-f) . However, during both RRP and reserve pool stimulations, facilitation of eEPSCs was stronger in control neurons than in AAV2/5 cells (Supplementary Fig. 8 ), suggesting that there are differences in short-term plasticity. Taken together, these results indicate that virus-induced reactive astrocytosis leads to a broad impairment of inhibitory, but not excitatory, neurotransmission.
Astrocytosis does not affect neuronal membrane properties
CA1 pyramidal neurons located in eGFP-positive areas were indistinguishable from neurons in naive mice in a number of membrane property measures ( Supplementary Table 1 and Supplementary  Fig. 9 ). Furthermore, intracellular labeling of control (n = 9) and AAV2/5 (n = 8) cells confirmed that pyramidal cell morphology, dendritic arborization and dense investiture of astrocytic processes adjacent to label-filled soma and neurites was maintained (Supplementary Fig. 10) . These results indicate that CA1 pyramidal neurons remain structurally and functionally viable and that their intrinsic properties are not altered by local astrocytosis. Figure 4 Preserved excitatory neurotransmission in CA1 pyramidal neurons proximal to reactive astrocytes. (a) Traces from a CA1 pyramidal cell in a control and an AAV2/5 slice recorded in the absence of glutamate and GABA A receptor antagonists (V hold = −40 mV). An eIPSC follows an eEPSC in each trace. Note that EPSCs are similar in amplitude, whereas IPSCs are reduced. (b,c) Histograms of eEPSC and eIPSC amplitude and charge transfer. eEPSC amplitudes and charge transfers were similar (eEPSC amplitude: control, n = 10; AAV2/5, n = 15; P = 0.34; eEPSC charge: control, n = 9; AAV2/5, n = 12; P = 0.59), whereas eIPSC amplitudes and charge transfer were both smaller in AAV2/5 cells (eIPSC amplitude: control, n = 6; AAV2/5, n = 12; *P = 0.014; eIPSC charge: control, n = 6; AAV2/5, n = 12; *P = 0.006). The AAV2/5 eIPSC average excluded two cells that failed to produce an eIPSC at stimulation intensities used to elicit an excitatory response. a r t I C l e S Changes in inhibitory synaptic strength in eGFP-positive areas of AAV2/5-treated mice could be generated by altered excitability of local interneurons. Multiple subtypes of hippocampal interneurons targeting pyramidal cell dendrites have been identified. We examined the somatostatin-containing oriens-lacunosum moleculare interneurons selectively labeled by eGFP in a transgenic mouse line, GIN 26 . Interneuron phenotype was verified anatomically (by GFP and Alexa 594 fluorescence) and physiologically by lack of action potential accommodation. We found no differences in seven basic electrophysiological parameters between six control neurons and five neurons in eGFP-positive areas of AAV2/5 slices (Supplementary Table 2 and Supplementary Fig. 11) , indicating that interneurons are unlikely to contribute to the inhibitory deficit observed in pyramidal cells in eGFP-positive areas.
Glutamate/glutamine cycle compromise impairs inhibition
Astrocytic glutamine maintains inhibitory efficacy in CA1 pyramidal cells and blockade of glutamine synthetase precipitates activitydependent failure of eIPSCs 8 . In control cells, blocking glutamine synthetase activity with methionine sulfoximine (MSO) decreased eIPSC amplitudes during and following the train stimulation to 50 ± 7% and 47 ± 6% of MSO-free responses, respectively (n = 8; Fig. 5a ). eGFP-positive reactive astrocytes from high-titer AAV2/5 mice downregulated glutamine synthetase expression ( Fig. 2i-l and Supplementary Fig. 6) , which should occlude the effects of MSO on eIPSCs. As expected, MSO treatment had no effect on eIPSCs recorded from CA1 neurons in eGFP-positive areas. eIPSC amplitudes in these cells during and following the train were 98 ± 12% and 107 ± 17% of MSO-free responses, respectively (n = 9; Figs. 3e and 5a) .
Decreased glutamine synthetase activity will deplete glutamine available for neuronal uptake. Because glutamine is converted to glutamate and then to GABA in inhibitory nerve terminals, glutamine deficiency reduces the pool of GABA available for synaptic release. We confirmed reduction in synaptic GABA by recording mIPSCs in the presence of (1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid (TPMPA), a low-affinity GABA A antagonist with a fast unbinding rate. Lower levels of synaptic GABA will result in a briefer synaptic cleft transient of GABA and a larger suppression of mIPSCs amplitude by TPMPA 8, 22 . Consistent with this prediction, TPMPA (30 µM) had a minimal effect on neurons from control slices (98.9 ± 8.5%, n = 6), but decreased mIPSC amplitude to 74.6 ± 4.2% of baseline in neurons from AAV2/5-injected mice (n = 6, P = 0.027). In contrast, a high-affinity GABA A antagonist, SR-95531 (300 nM), blocked mIPSCs equivalently in AAV2/5 and control groups (AAV2.5: 81.5 ± 5.4%, n = 5; control: 81.7 ± 3.3%, n = 6, P = 0.97; Fig. 5b ).
If neuronal glutamine starvation mediates eIPSC failure, eIPSCs should be rescued by exogenous glutamine. Bath application of glutamine (10 mM) increased eIPSC amplitude to 126 ± 6% of pretreatment levels in 7 of 11 CA1 neurons in eGFP-positive areas of AAV2/5 slices. Glutamine had no effect on control neurons (91 ± 4%, n = 7, group effects differ, P < 0.001; Fig. 5c ). Glutamine application also attenuated the dynamic failure of eIPSCs following train stimulation ( Fig. 5c ) to 88.6 ± 8.6% of pre-train baseline (n = 5, P = 0.04 relative to AAV2/5 neurons in the absence of glutamine) but failed to reverse the reduction of eIPSC amplitudes during the train (Fig. 5c) . The latter may suggest gliosis-triggered recruitment of glutamine cycle-independent mechanisms modulating short-term synaptic plasticity (see Discussion). These results indicate that reactive astrocytosis-induced glutamine synthetase reduction leads to interrupted neuronal glutamine supply, impaired neuronal production of GABA and compromised inhibitory neurotransmission.
Virus-induced astrocytosis alters network excitability
To evaluate whether the inhibitory deficits observed at a cellular level translate into altered network function, we examined CA1 circuit activity triggered by temporoammonic pathway (TAP) stimulation, using voltage-sensitive dye (VSD) imaging techniques. TAP activation of CA1 network responses is strongly regulated by feedforward inhibition, which constrains excitatory postsynaptic potentials (EPSPs) to distal dendrites of CA1 pyramidal cells 27, 28 . Loss of inhibitory control over TAP signaling following induction of astrogliosis should result in a more powerful excitation, similar to that observed in slices from with cells that were not exposed to MSO during and following train stimulation. Right, effect of train stimulation on eIPSC amplitudes following incubation in MSO (1.5 mM) is expressed as the percentage change from eIPSCs recorded in the absence of MSO (Fig. 3e) . MSO triggered an activity-dependent decrease of eIPSC amplitude in control cells, but not AAV2/5 cells (**P < 0.001 relative to control). (b) Left, mIPSC averages in the absence (thin traces) and presence (thick traces) of TPMPA and SR95531. Right, TPMPA significantly reduced mIPSC amplitude in neurons from AAV2/5 eGFP-positive cells (AAV2/5 (+/-TPMPA), 9.5 ± 1.2 pA/7.1 ± 0.9 pA, n = 6, P = 0.005, paired t test; control (+/-TPMPA), 12.5 ± 1.6 pA/12.2 ± 2 pA, n = 6, P = 0.87, paired t test). SR95531 reduced mIPSC amplitude to a similar extent in both groups of cells (AAV2/5 (+/-SR95531), 12.3 ± 1.4 pA/9.9 ± 1.4 pA, n = 5, P = 0.033, paired t test; control (+/-SR95531), 13.6 ± 2.1 pA/11.1 ± 1.8 pA, P = 0.004, paired t test). *P = 0.027 compared with controls. (c) Left, current traces before (thin trace) and during (thick trace) application of 10 mM glutamine. Middle, supplementation with glutamine partially reversed eIPSC failure in a subset of AAV2/5 cells (**P < 0.001 relative to control; AAV2/5, n = 7; control, n = 7). Right, bath-applied glutamine restored eIPSC amplitudes to control levels following train stimulation, but failed to prevent eIPSC failure during the train (**P ≤ 0.003 relative to control, # P = 0.04 relative to AAV2/5). Cell numbers (train/post-train) are as follows: control, n = 12/10; AAV2/5, n = 10/6; AAV2/5 and glutamine, n = 6/5. Error bars represent s.e.m.
a r t I C l e S epileptic animals 28 . Following TAP stimulation, we recorded sustained EPSPs propagating to stratum radiatum and stratum oriens in 63% (10 out of 16) of eGFP-positive slices from five mice. In all six control slices, EPSPs propagated only to distal stratum radiatum and elicited an inhibitory postsynaptic potential (IPSP) in stratum oriens of area CA1 (Fig. 6a-c) . In stratum oriens, IPSPs observed in control slices converted to EPSPs in astrogliotic slices (control dF/F = −0.024 ± 0.005%, n = 6; AAV2/5 dF/F = 0.064 ± 0.014%, n = 10; P < 0.001; Fig. 6d ). This was accompanied by a 20-fold increase in the area activated by TAP stimulation in the AAV2/5 group (P < 0.002; Fig. 6e ).
Whole-cell current-clamp recordings from CA1 pyramidal neurons confirmed that TAP activation triggered an EPSP in neurons located proximal to reactive astrocytes and an IPSP in control neurons (controls, −2.7 ± 0.8 mV, n = 3; AAV2/5, 2.1 ± 0.5 mV, n = 6; Fig. 6c ).
We examined whether exogenous glutamine would reverse the circuit hyperexcitability associated with reactive gliosis. In eGFPpositive slices, application of 10 mM glutamine reduced the stratum radiatum and stratum oriens EPSPs to 64 ± 14% and 43 ± 15% of pre-glutamine levels (n = 5, no effect in 1 slice; Fig. 6f,g) and similarly reduced the activated areas (radiatum, 68 ± 20%; oriens, 47 ± 15% of pre-glutamine levels; Fig. 6h ). Thus, inhibitory deficits associated with reactive gliosis lead to hyperexcitability of the hippocampal network and this can be partially ameliorated by exogenously supplied glutamine.
DISCUSSION
Virus-induced reactive astrocytosis triggered a selective deficit in inhibitory synaptic transmission in hippocampal neurons. This occurred in the absence of potentially confounding pathophysiologic effects of brain injury and/or inflammation, which usually accompany the development of astrocytosis. Impaired inhibitory neurotransmission was a result of a disruption of the astrocytic glutamate/glutamine cycle, mediated by glutamine synthetase downregulation in reactive astrocytes. This led to reduced availability of glutamine for neuronal uptake and concomitant reduced synaptic GABA availability. The compromised glutamate/glutamine cycle function and associated failure of inhibition resulted in network hyperexcitability similar to that seen in animal models of TLE 28 .
Specific association of astrocytosis and synaptic deficits
The mechanism underlying virus-induced reactive astrocytosis is not known. Two possible mechanisms are capsid interactions with cellular receptors that lead to preferential viral transduction or viral DNA interacting with toll-like receptors. Regardless of mechanism, our data are consistent with an astrocytic basis for reactivity. When using AAV2/9, which selectively transduces neurons, reactive astrocytosis was not detected. Thus, it is the interaction of the virus with the astrocyte that is important for the resulting reactive astrocytosis. When we performed experiments using AAV2/5 and the CMV promoter, we did not detect expression in microglia (data not shown), thus we can discount this cell type as contributing to the process. There is a remote possibility that the few neurons that can be transduced by AAV2/5 would have led to reactive astrocytosis. If this were the case, however, we would expect the neurons to also affect the microglia. We did not detect a stimulation of CD45 staining of microglia and therefore feel that such a scenario is not likely.
Using AAV as a selective tool to generate reactive astrocytosis isolated from other pathologic processes allowed us to determine whether changes in synaptic transmission specifically accompany astrocytic reactivity. Glutamine synthetase expression was reduced in astrocytes and there was a correlated reduction in inhibitory transmission. In two tests of a causal relationship, the effects of glutamine cycle antagonists on inhibitory function were occluded in regions of reactive gliosis and exogenous glutamine led to a partial recovery of synaptic function. As glutamine is selectively synthesized in astrocytes, these results support our conclusion that reactive astrocytosis leads to impaired inhibitory synaptic transmission as a consequence of reduced glutamine synthetase expression and a r t I C l e S glutamine supply. In addition, we found that astrocytosis led to changes in network excitability, which could be attenuated by exogenous glutamine (Fig. 6) .
Astrocytosis-triggered IPSC failure
Several variables must be considered when interpreting the potential effects of virally induced reactive gliosis on inhibition. First, there are multiple vesicle populations in inhibitory terminals, including the readily releasable and recycling pools that were sampled in our studies. GABA content in these distinct pools may derive from differing sources and so exhibit differential sensitivity to gliosis. Second, the viral strategy activates many, but not all, astrocytes and, as astrocytes occupy non-overlapping synaptic territories 29 , some of the neuron's inhibitory synapses may be metabolically dependent on reactive astrocytes and some on remaining unaffected astrocytes. This could contribute to variation in the degree of effect of gliosis on small versus large amplitude IPSCs.
Assuming that postsynaptic receptors are unchanged, we hypothesize that deficits in presynaptic GABA levels will be predominantly evident during IPSCs elicited by nonsaturating neurotransmitter concentrations, that is, small amplitude events. At these synapses, neurotransmitter concentration determines IPSC amplitude and gliosisinduced decrease in synaptic GABA directly translates to smaller responses. In contrast, at synapses that function in a suprasaturated state, a fractional reduction in vesicular GABA as a result of gliosis might still be sufficient to fully occupy postsynaptic receptors (that is, receptor availability, rather than neurotransmitter concentration, is rate limiting). Thus, large-amplitude events would tend to be less affected than small-amplitude events. Our data are consistent with these predictions and are bolstered by examination of quantal synaptic events, mIPSCs. In AAV2/5 neurons, the mIPSC amplitude distribution was left-shifted as a result of an increased contribution of small-amplitude events. In addition, the fast-off, low-affinity GABA A antagonist, TPMPA, was more effective in AAV2/5 than in control neurons, whereas the high-affinity GABA A antagonist, SR95531, was equally effective in both groups of neurons. Both of these effects would be expected from reduced GABA levels in a population of synapses or in a subset of synaptic vesicles 22, 30, 31 .
Lack of effect of virus-induced astrocytosis on EPSCs
Preservation of EPSCs in cells proximal to reactive astrocytes exhibiting glutamine synthetase downregulation corroborates a recent study that found that excitatory signaling is not affected by glutamate/ glutamine cycle inhibitors 10 . Together with our results, these data suggest that GABAergic signaling relies on astrocyte-derived glutamine to a greater extent than glutamatergic synapses, which may depend more on direct uptake of glutamate into neurons and/or have a higher basal cytoplasmic reserve of this amino acid than interneurons.
We observed no differences in excitatory drive onto CA1 pyramidal cells following stimulation of the RRP and the reserve pool of vesicles. However, pyramidal cells neighboring reactive astrocytes showed reduced short-term facilitation of eEPSCs during the RRP and the early stage of the reserve pool trains (Supplementary Fig. 8 ), suggesting that there was a higher initial release probability of glutamate-containing vesicles 32 . Notably, a similar alteration in shortterm plasticity was evident for IPSCs. In cells from eGFP-positive slices, train-induced eIPSC facilitation (Fig. 3e ) was reduced and this was not rescued by exogenous glutamine (Fig. 5c) . These findings indicate that development of astrocytosis alters both excitatory and inhibitory short-term synaptic plasticity through mechanisms that are independent of the astrocyte-derived glutamine.
Experimental astrocytosis accompanied by brain inflammation has been induced by systemic injection of the bacterial endotoxin lipopolysaccharide (LPS). This increases both excitatory and inhibitory drive in the hippocampus 33, 34 . LPS triggers both inflammation and astrocytosis, unlike AAV2/5-induced astrocyte reactivity, which generated astrocytosis in the absence of microglial activation. Moreover, LPS effects are distributed broadly throughout the brain, whereas AAV2/5 is relatively local. This underscores the importance of distinguishing between neuronal deficits precipitated by a global brain pathology accompanied by inflammation and those specifically associated with local glial reactivity.
Reactive astrocytes are associated with many disease and injury states and have been implicated in the maintenance of epileptic seizure foci 16, 35 . Our results suggest a specific association of virus-induced reactive astrocytosis with a deficit of inhibitory, but not excitatory, neurotransmission. The inhibitory deficit was spatially restricted to areas of high astrocytic reactivity and was precipitated by decreased synthesis of glutamine in astrocytes. By starving inhibitory synapses of glutamine, reactive astrocytes exert a powerful control over the efficacy of GABAergic synapses. Given the importance of GABAergic inhibition in neuronal circuit regulation, the altered role reactive astrocytes have in regulating synaptic function is likely to have functional consequences in CNS disease states associated with astrocytosis, potentially eroding many emergent functions of neuronal circuits, such as cognition, learning and memory, movement generation and coordination, and resistance to seizure generation.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
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